Clinical Trials
19 trialsNCT05521698 2026-06-04
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Phase 1 Recruiting
NCT04514484 2026-05-28
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02298959 2026-05-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02496208 2026-05-13
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04963153 2026-05-13
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06439836 2026-05-13
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06982222 2026-05-13
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07128680 2026-05-11
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07219147 2026-04-20
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06049576 2026-04-15
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06105918 2025-12-09
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Emory University
Phase 1 Active not recruiting
NCT05805371 2025-11-19
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT06942104 2025-07-18
Imaging of Solid Tumors Using 18F-TRX
University of California, San Francisco
Phase 1 Recruiting
NCT06094842 2025-04-01
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT06399419 2024-05-30
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Osel, Inc.
Phase 1 Recruiting
NCT05807126 2024-05-02
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated